Investor’s Alert: Facebook (NASDAQ:FB), Tiffany & Co. (NYSE:TIF), Silver Wheaton (USA) (NYSE:SLW), Cellceutix (OTCMKTS:CTIX)

In the purview of recent WhatsApp acquisition made by Facebook Inc. (NASDAQ:FB), company is set to increase its share of overall internet time which is around 18% without including WhatsApp and Instagram. Facebook (NASDAQ:FB) is also expected to bring new play video format ads which is expected to increase ad revenues further for Facebook. Taking into account Instagram and WhatsApp as well total minutes for Facebook grew by over 30% for the year 2013. Facebook Inc (NASDAQ:FB) shares after opening at $67.53 moved to $67.92 on last trade day and at the end of the day closed at $67.24. Company price to sales ratio in past twelve months was calculated as 21.00 and price to cash ratio as 14.44.Facebook Inc (NASDAQ:FB) showed a negative weekly performance of -0.71%.

Tiffany & Co. (NYSE:TIF) announced its earnings results on Friday. The company reported ($0.81) earnings per share for the quarter, missing the analysts’ consensus estimate of $1.52 by $2.33, ARN reports. The company had revenue of $1.30 billion for the quarter, compared to the consensus estimate of $1.31 billion. During the same quarter last year, the company posted $1.40 earnings per share. Tiffany & Co. (NYSE:TIF) shares fell -0.48% in last trading session and ended the day on $90.73. TIF return on equity ratio is recorded as 6.60% and its return on assets is 3.80%. Tiffany & Co. (NYSE:TIF) yearly performance is 35.78%.

Cowen and Company lowered their price target on shares of Silver Wheaton Corp. (NYSE:SLW) from $28.63 to $26.25 in a research note issued on Monday, StockRatingsNetwork reports. The firm currently has a “market perform” rating on the stock. Cowen and Company’s price objective suggests a potential upside of 4.62% from the company’s current price. Silver Wheaton Corp. (USA) (NYSE:SLW) shares moved down 0.04% in last trading session and was closed at $25.04, while trading in range of $24.80-$25.55. Silver Wheaton Corp. (USA) (NYSE:SLW) year to date performance is 24.02%.

Cellceutix Corp (OTCMKTS:CTIX) is an early-stage developmental biopharmaceutical company. The Company has acquired exclusive rights to eight different pharmaceutical compound candidates that are designed for treatment of diseases which exist, or may exist in the future. The Company focuses on Phase 1 trial at Dana Farber Cancer Center and Beth Israel Deaconess Hospital for its anti-cancer compound, Kevetrin. Cellceutix Corp (OTCMKTS:CTIX) On last trading day company shares ended up $1.81.